PDF(1438 KB)
Immune dysregulation syndrome caused by STAT3 gene mutation: a complicated case study
YAO An-Qi, CHEN Ke-Ke, HE Xiang-Ling, TIAN Xin
Chinese Journal of Contemporary Pediatrics ›› 2021, Vol. 23 ›› Issue (4) : 397-401.
PDF(1438 KB)
PDF(1438 KB)
Immune dysregulation syndrome caused by STAT3 gene mutation: a complicated case study
A boy, aged 4 years and 6 months, had disease onset of fever, cough, pale complexion, and weakness, with hepatosplenomegaly, lymphadenectasis, and pancytopenia. He had been having repeated respiratory and digestive tract infections. Gene detection showed a pathogenic heterozygous mutation, c.C2147 > T(p.T716M), in the STAT3 gene. The boy was thus diagnosed with immune dysregulation syndrome. Anti-infective therapy and irregular corticosteroid therapy had an unsatisfactory effect in the early stage, but the symptoms improved after regular corticosteroid therapy. This article reported the case of immune dysregulation syndrome caused by STAT3 gene mutation and summarized the epidemiology, clinical features, diagnosis, and treatment of this disease, which can provide a reference for early diagnosis, treatment, and future studies of this disease.
Immune dysregulation syndrome / Pancytopenia / Lymphadenectasis / Hepatosplenomegaly / Recurrent infection / STAT3 gene / Child
[1] Bousfiha A, Jeddane L, Al-Herz W, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies[J]. J Clin Immunol, 2015, 35(8):727-738.
[2] Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease[J]. Nat Genet, 2014, 46(8):812-814.
[3] 丁媛, 张宇, 王艳平, 等. STAT3基因功能获得性突变致免疫失调性疾病临床及免疫学特征研究[J]. 中华儿科杂志, 2017, 55(1):30-36.
[4] Fabre A, Marchal S, Barlogis V, et al. Clinical aspects of STAT3 gain-of-function germline mutations:a systematic review[J]. J Allergy Clin Immunol Pract, 2019, 7(6):1958-1969.e9.
[5] Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations[J]. Blood, 2015, 125(4):591-599.
[6] 王秋菊, 沈亦平, 邬玲仟, 等. 遗传变异分类标准与指南[J]. 中国科学:生命科学, 2017, 47(6):668-688.
[7] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[8] 胡宛如, 何莉, 张乾忠. 与感染相关的全血细胞减少[J]. 中国实用儿科杂志, 2011, 26(10):743-745.
[9] 何庭艳, 赵晓东, 杨军. 原发性免疫缺陷病分类更新(2019版)解读[J]. 中华儿科杂志, 2020, 58(8):624-627.
[10] Haddad E. STAT3:too much may be worse than not enough![J]. Blood, 2015, 125:583-584.
[11] Gutiérrez M, Scaglia P, Keselman A, et al. Partial growth hormone insensitivity and dysregulatory immune disease associated with de novo germline activating STAT3 mutations[J]. Mol Cell Endocrinol, 2018, 473:166-177.
[12] Weinreich MA, Vogel TP, Rao VK, et al. Up, down, and all around:diagnosis and treatment of novel STAT3 variant[J]. Front Pediatr, 2017, 5:49.
[13] Sediva H, Dusatkova P, Kanderova V, et al. Short stature in a boy with multiple early-onset autoimmune conditions due to a STAT3 activating mutation:could intracellular growth hormone signalling be compromised?[J]. Horm Res Paediatr, 2017, 88(2):160-166.
[14] Fabre A, Marchal S, Forbes LR, et al. STAT3 gain of function:a new kid on the block in interstitial lung diseases[J]. Am J Respir Crit Care Med, 2018, 197(11):e22-e23.
[15] Forbes LR, Vogel TP, Cooper MA, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1(STAT1) or STAT3 mutations[J]. J Allergy Clin Immunol, 2018, 142(5):1665-1669.
